araag2/HINT huggingface dataset:
Clinical trial NCT02308098 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, symbicort turbuhaler 320/9 ug/inhalation 4 inh, symbicort turbuhaler 320/9 ug/inhalation 1inh, placebo symbicort turbuhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, placebo symbicort turbuhaler 320/9 ug/inhalation 1 inh
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main inclusion criteria:

          -  Written informed consent

          -  Asthma diagnosis for at least 6 months

          -  Prebronchodilator FEV1 45-90% of the predicted value

          -  Demonstration of reversible airway obstruction

          -  Stable asthma on the same regular treatment for at least 4 weeks before the study

          -  Non-smoker for at least 6 months before the study

        Main exclusion criteria

          -  Respiratory infection within 4 weeks before the study

          -  Smoking history of more than 10 pack-years

          -  Other severe chronic respiratory disease than asthma

          -  Concurrent illness that would interfere with the interpretation of the study results
             or constitute a health risk for the patient if he/she takes part in the study

          -  Corrected QT interval > 450 ms in males or > 470 ms in females

          -  Abnormal serum potassium value or other clinically significant laboratory finding

          -  Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg

          -  Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a
             corticosteroid (other than inhaled) within 4 weeks before the study

          -  Use of drugs that prolong QT-interval

          -  Women who are pregnant, breast-feeding or without reliable contraception

          -  Participation in another clinical drug study
Clinical trial NCT02313909 (phase 3, status: terminated)
Conditions: stroke
ICD codes: G46.4, G46.3, Z82.3
Drugs: rivaroxaban (xarelto, bay59-7939), acetylsalicylic acid (aspirin, bay1019036)
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CC(=O)OC1=CC=CC=C1C(O)=O
Reason stopped: 
    study halted early due to no efficacy improvement over aspirin at an interim analysis and very
    little chance of showing overall benefit if study were completed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Recent ESUS (between 7 days and 6 months), defined as:

          -  Recent ischemic stroke (including transient ischemic attack with positive
             neuroimaging) visualized by brain imaging that is not lacunar, and

          -  Absence of cervical carotid atherosclerotic stenosis> 50% or occlusion, and

          -  No atrial fibrillation after ≥ 24-hour cardiac rhythm monitoring, and

          -  No intra-cardiac thrombus on either transesophageal or transthoracic echocardiography,
             and

          -  No other specific cause of stroke (for example, arteritis, dissection,
             migraine/vasospasm, drug abuse)

        Exclusion Criteria:

          -  Severely disabling stroke (modified Rankin score ≥4)

          -  Indication for chronic anticoagulation or antiplatelet therapy

          -  Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2
Clinical trial NCT02314819 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fruquintinib, placebo
SMILES: CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 and ≤ 75 years of age , with ≥ 40Kg

          -  Histological or cytological confirmed colorectal cancer

          -  ECOG performance status of 0-1

          -  Standard regimen failed or no standard regimen available

          -  Adequate hepatic, renal, heart, and hematologic functions

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  Signed and dated informed consent

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedure

        Exclusion Criteria:

          -  - Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Evidence of CNS metastasis

          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery
             disease, arrhythmia and heart failure

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR
             inhibition

          -  Disability of serious uncontrolled intercurrence infection

          -  Proteinuria ≥ 2+ (1.0g/24hr)

          -  Have evidence or a history of bleeding tendency within two months of the enrollment,
             regardless of seriousness

          -  Within 12 months before the first treatment occurs artery/venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack) etc.

          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute
             coronary syndrome or CABG

          -  Bone fracture or wounds that was not cured for a long time

          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
Clinical trial NCT02316899 (phase 3, status: completed)
Conditions: irritable bowel syndrome with constipation (ibs-c)
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: linaclotide, placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who had abdominal pain or discomfort repeatedly for at least 3 days per month
             during the 3 months before screening examination associated with at least 2 out of the
             following 3 conditions: (1) Improvement with defecation; (2) Onset associated with a
             change in frequency of stool; and (3) Onset associated with a change in form
             (appearance) of stool, and had the above symptom (IBS symptom) 6 months or more before
             the screening examination period

          -  Patients with ≥ 25% of stools hard or lumpy (with each bowel movement occurring
             without antidiarrheal, laxative, suppository or enema) and <25% of them loose (mushy)
             or watery during the 3 months before the screening examination

          -  Patients who had pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset
             of IBS symptom and had no organic changes

        Exclusion Criteria:

          -  Patient with history of surgical resection of stomach, gallbladder, small intestine,
             or large intestine (excluding resection of appendicitis and benign polyp)

          -  Patient with history or current affection of inflammatory bowel disease (Crohn's
             disease or ulcerative colitis)

          -  Patient with history or current affection of ischemic colitis

          -  Patient currently affected by infectious enteritis

          -  Patient currently affected by hyperthyroidism or hypothyroidism

          -  Patient currently affected by active peptic ulcer

          -  In the case of a female patient, the one currently affected by endometriosis or
             uterine adenomyosis

          -  Patient with high depression or anxiety considered to influence drug evaluation

          -  Patient with history of abuse of drug or alcohol within a year before consent
             acquisition, or with current abuse

          -  Patient who used or underwent or will use or undergo drug/therapy/test prohibited to
             combine 3 days before the start of bowel habit observation period (Day -17) or
             thereafter

          -  Patient with history or current affection of malignant tumor

          -  Patient currently affected by serious cardiovascular disease, respiratory disease,
             kidney disease, hepatic disease, gastrointestinal disease (excluding IBS), hemorrhagic
             disease, or neural/mental disease

          -  Patient with history of drug allergy
Clinical trial NCT02318602 (phase 3, status: completed)
Conditions: seizures
ICD codes: G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: cannabidiol oral solution
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Completed activities through Day 11 in INS011-14-029 or Part A (Visit 6) INS011-15-054

          -  Informed consent/assent (as applicable) was voluntarily provided by the participant
             and/or parent(s)/caregiver(s) in accordance with applicable laws, regulations, and
             local requirements

          -  Is medically stable with no anticipated changes in chronic medications in the opinion
             of the Investigator

          -  Continues to meet protocol-specified criteria for qualification and contraception,
             including treatment-resistant seizure disorder

          -  In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able
             to continue keeping accurate seizure diaries

        Exclusion Criteria:

          -  Inadequate supervision by parent(s)/caregiver(s)

          -  History or current use of dietary supplements, drugs or over-the counter medications
             outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding)

               3. the analysis of results
Clinical trial NCT02318706 (phase 3, status: completed)
Conditions: diabetic peripheral neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: ds-5565, placebo
SMILES: CCC1=C[C@@H]2[C@@H](C[C@]2(CN)CC(O)=O)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 or type 2 diabetes mellitus at screening

          -  Painful distal symmetric polyneuropathy

          -  At screening, a pain scale of ≥ 40 mm

        Exclusion Criteria:

          -  HbA1c (National Glycohemoglobin Standardization Program) > 10.0%
Clinical trial NCT02319031 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, sofosbuvir, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have Genotype 3 Chronic HCV

          -  Must have advanced fibrosis (F3) or compensated cirrhosis (F4)

          -  HCV RNA Viral load ≥ 10,000 IU/mL

          -  HCV Treatment naive or treatment-experienced

        Exclusion Criteria:

          -  Non Genotype 3 or mixed genotypes

          -  Non advanced fibrosis or compensated cirrhosis

          -  Any prior treatment with NS5A inhibitors
Clinical trial NCT02319187 (phase 3, status: unknown status)
Conditions: esophageal neoplasms
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: s1, s-1, irinotecan
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven esophageal squamous cell carcinoma;

          -  18 ≤ age ≤ 70;

          -  ECOG 0-2;

          -  Previously Treated with platinum or paclitaxel based regimen;

          -  Uni-dimensionally measurable disease (CT or MRI as per RECIST);

          -  Patients should have a projected life expectancy of at least 3 months;

          -  Completion of baseline quality of life questionnaire

          -  Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul,
             haemoglobin ≥ 10g/dl);

          -  Adequate renal functions(serum creatinine ≤ 1.5mg/dl)

          -  liver functions (serum bilirubin ≤ 1.5UNL, AST/ALT ≤ 3 times(normal value)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy with 5-FU or irinotecan after recurrence or metastasis;

          -  adjuvant chemotherapy with 5-FU-based chemotherapy within 6 months prior to the start
             of study treatment;

          -  Active infection requiring antibiotics

          -  Pregnant, lactating women

          -  Psychiatric illness, epileptic disorders

          -  Concurrent systemic illness not appropriate for chemotherapy

          -  History of other malignancy within 5 years except for non-melanoma skin cancer, cervix
             in situ carcinoma
Clinical trial NCT02320396 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: desloratadine 5 mg, placebo
SMILES: ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has at least a 2-year history of seasonal allergic rhinitis with typical symptoms

          -  Male or female who is unlikely to conceive: a surgically sterilized female, female who
             has reached natural menopause, or is of reproductive potential and agrees to either
             remain abstinent or use (or have her partner use) 2 acceptable methods of birth
             control from study start through 14 days after the last dose of study drug.

        Exclusion Criteria:

          -  Has a lower respiratory tract infection or has a nasopharyngolaryngeal infection
             (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute
             tonsillitis, etc.) requiring treatment

          -  Has a coexisting infection or systemic mycosis for which there are no effective
             antibiotics

          -  Has asthma that is under treatment and/or uncontrolled

          -  Has nasal septum ulcers, nasal surgery, or nasal trauma which have not healed

          -  Has vasomotor rhinitis or eosinophilic rhinitis

          -  Has a history of hypersensitivity to antihistamines or ingredients of study drug

          -  Has had treatment with corticosteroids (oral, injectable, suppository, depot drugs
             [injectable]) or immunological drugs within 28 days prior to Visit 2

          -  Is currently receiving treatment with another investigational drug or has received an
             investigational drug within prior 3 months

          -  Has started specific desensitization therapy (allergen immunotherapy) or nonspecific
             allassotherapy (Histaglobin, vaccine therapy, etc.) or who has received such therapies
             within prior 3 months

          -  Has received coagulation or resection using laser therapy etc. for treatment for nasal
             symptoms

          -  Will receive nasal nebulizer therapy and/or thermotherapy during study period

          -  Has severe hepatic, renal, cardiac, hematological disease, or other serious coexisting
             diseases and whose general condition is poor

          -  Has a history of malignancy or clinically important hematological disorder, except for
             adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix

          -  Has a history of severe drug allergy (e.g. anaphylactoid reaction)

          -  Is pregnant or lactating or may be pregnant

          -  Is planning a remote trip for more than 1 day during the Symptom Confirmation Period
             or for more than 2 days during the Treatment Period.
Clinical trial NCT02320721 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine (hoe901 - u300), insulin glargine (hoe901 - u100), background therapy
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants ≥65 years old with type 2 diabetes mellitus, inadequately controlled on
             antidiabetic regimens either including no insulin, or with basal insulin as their only
             insulin.

          -  Signed informed consent.

        Exclusion criteria:

          -  HbA1c at screening visit:

               -  <7.0% or >10.0% for participants taking basal insulin.

               -  <7.5% or >11.0% for insulin-naïve participants.

          -  History of type 2 diabetes mellitus for less than 1 year before screening.

          -  Participants not on stable basal insulin dose (±10% in the last 8 weeks prior to
             screening visit).

          -  Change in dose of antidiabetic treatment or initiation of new glucose-lowering
             medications in the last 8 weeks prior to screening.

          -  Chronic (>10 days continuous use in previous 6 months) use of bolus insulin
             injections, whether given separately or as part of a combination with basal insulin,
             e.g. premix insulin; For insulin-naïve individuals: current or previous insulin use
             except for a maximum of 10 consecutive days (e.g. acute illness, surgery) during the
             last year prior to screening.

          -  Cognitive disorder and dementia assessed clinically and by Mini-Mental State
             Examination (MMSE) score <24, or any neurologic disorder that would likely affect the
             participant's ability to follow the study procedure. The participant would be eligible
             despite an MMSE score <24 if the investigator determined that the low score reflected
             educational or cultural background and not dementia as long as the participant was
             otherwise able to meet the study requirements.

          -  Participants who had end-stage renal disease (<15 mL/min/1.73m^2, per estimated
             Glomerular filtration rate (eGFR) measurement by Modification of Diet in Renal Disease
             (MDRD).

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02322320 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

        Patients fulfilling the following criteria will be eligible to provide continued long-term
        follow-up data as part of this study:

          1. Enrolled and randomized on the BMT CTN 0702 protocol.

          2. Alive at the completion of BMT CTN 0702 protocol specified follow-up defined as 4
             years post-randomization.

          3. Patients without evidence of disease progression at the completion of BMT CTN 0702
             protocol specified follow up.

          4. Signed Informed Consent Form.

          5. Patients with the ability to speak English or Spanish are eligible to participate in
             the HQL component of this trial.

        Inclusion Criteria for Optional Long-term Lenalidomide Maintenance Therapy:

        Patients fulfilling the following criteria will be eligible to provide continued long-term
        follow-up data AND receive long-term lenalidomide maintenance therapy as part of this
        study:

          1. Enrolled and randomized to BMT CTN 0702.

          2. Completion of 3 years of maintenance therapy on BMT CTN 0702.

          3. Registered in the mandatory Revlimid REMS® program (formerly the RevAssist® for Study
             Participants (RASP) program), and be willing and able to comply with the requirements
             of the Revlimid REMS® program, including counseling, pregnancy testing, and phone
             surveys.

          4. Signed informed consent form.

          5. Patients with the ability to speak English or Spanish are eligible to participate in
             the HQL component of this trial.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be ineligible to receive long-term
        lenalidomide maintenance therapy as part of this study:

          1. Patients who have evidence of disease progression prior to enrollment.

          2. Patients who were discontinued from BMT CTN 0702 lenalidomide maintenance therapy, for
             any reason, prior to the completion of the 3 years of 0702 maintenance.

          3. Female patients who are pregnant (positive - Beta Human Chorionic Gonadotropin) or
             breastfeeding.

          4. Females of childbearing potential (FCBP) or men who have sexual contact with FCBP
             unwilling to use contraceptive techniques during the length of lenalidomide
             maintenance therapy.

          5. Patients who experienced thromboembolic events while on full anticoagulation during
             prior therapy with lenalidomide.

          6. Patients unwilling to take Deep Vein Thrombosis (DVT) prophylaxis.

          7. Patients who developed a second primary malignancy, excluding non-melanoma skin
             cancers after initiation of lenalidomide maintenance therapy on BMT CTN 0702.
Clinical trial NCT02322593 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: tas-118 plus oxaliplatin, s-1 plus cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patients who are diagnosed as gastric cancer.

          -  No prior treatment for gastric cancer.

          -  Negative or unknown for HER2 testing.

          -  ECOG performance status of 0 or 1.

        Key Exclusion Criteria:

          -  Unmanageable diarrhea.

          -  Current peripheral sensory neuropathy or paresthesia.

          -  Pregnant or lactating female.